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Abstract: Studies have highlighted the essential nature of a group of small, highly hydrophobic,
membrane embedded, channel-forming proteins in the life cycles of a growing number of RNA
viruses. These viroporins mediate the flow of ions and a range of solutes across cellular membranes
and are necessary for manipulating a myriad of host processes. As such they contribute to all
stages of the virus life cycle. Recent discoveries have identified proteins encoded by the small DNA
tumor viruses that display a number of viroporin like properties. This review article summarizes
the recent developments in our understanding of these novel viroporins; describes their roles in
the virus life cycles and in pathogenesis and speculates on their potential as targets for anti-viral
therapeutic intervention.
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1. Introduction
As obligate intracellular parasites, viruses have evolved a myriad of strategies to manipulate the
host cell environment to one that is conducive for virus replication. Research over recent decades has
identified a group of virus-encoded proteins able to mediate the passage of ions and solutes across
cellular membranes, termed viroporins [1,2]. The majority of viroporins described are small (less than
120 amino acids) and contain one or two transmembrane domains (TMD), although a small number
of larger viroporins have been shown to encode up to three putative TMD [3]. Whilst high-resolution
structural information is currently only available for a limited number of viroporins [4–8], a
bio-informatic approach has often been successfully employed to identify key features in viroporins
that lack any structural information [1,3]. Their small size necessitates that viroporins must
oligomerize in membranes to form an active channel complex. Formation of these high-order
complexes is often observed in mild detergents such as 1,2-diheptanoyl-sn-glycero-3-phosphocholine
(DHPC) [3,9] and is likely to be mediated by hydrophobic interactions between the TMD of each
monomer; although in some viroporins basic residues adjacent to the TMD may facilitate membrane
binding and insertion [10,11]. Known viroporins have been placed into distinctive classes based
on the number of TMD and the orientation of their carboxyl termini relative to the endoplasmic
reticulum (ER) membrane [2]. Undoubtedly, this classification system is useful for cataloguing the
expanding number of viroporins, however, it will need to adapt in order to accommodate those few
viroporins encoding three TMD and it will also need to take into account the dynamic nature of
membrane proteins in lipids, which are capable of altering the orientation of their termini depending
on the lipid environment [3,12].
Modulation of ionic homeostasis within specific cellular compartments allows for viroporins
to manipulate a wide range of cellular processes from autophagy [13–15], trafficking [16,17],
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inflammation [18,19], transformation [3] to cell survival [20]. Due to these broad perturbations to host
cell physiology, it is not surprising that viroporin function has been shown to assist in all stages of the
virus life cycle including entry, membrane penetration, genome replication and virus egress [1,2].
The existence of virus encoded pore-forming proteins was initially postulated nearly four
decades ago [21]. However, it was observations that the M2 protein of Influenza A virus (IAV)
was able to form a tetramer [22] and raise intracellular pH [23,24] that provided the first clues to its
role as an ion channel. Pioneering studies in Xenopus oocytes demonstrated M2-dependent currents
that could be blocked by addition of the anti-viral compound Amantadine [25]. Following this,
viroporins were swiftly identified from a number of RNA virus families. Whilst IAV M2 remains
the paradigm, viroporins have now been described in a number of virus families including the
Flaviviridae, Picornaviridae, Retroviridae, Coronaviridae, Reoviridae and Paramyxoviridae [1,26–32]. To
date, the overwhelming majority of viroporins have been identified in RNA viruses. However, given
the myriad of cellular processes that they are able to modulate, it is logical to assume that all viruses
might benefit from encoding such a protein. Recent findings have now identified proteins that exhibit
a number of viroporin characteristics encoded by members of the Polyomaviridae and Papillomaviridae.
This review will summarize our understanding of these putative viroporins, describe their known
functions and attempt to highlight how possible ion channel activity may aid the life cycles of these
small DNA tumor viruses.
2. Polyomaviruses
The Polyomaviridae are small, non-enveloped, double-stranded DNA viruses that infect a wide
range of species [33]. The family was named after the founding member, polyomavirus, which
caused “many tumors” in mice [34], followed by the prototypic primate polyomavirus, Simian
Vacuolating agent 40 (SV40), from the rhesus monkey [35]. The first two human polyomaviruses
discovered in 1971, JC and BK, were named after the index cases, and cause serious disease in
the immunocompromised [36]. The last decade has seen the discovery of several novel human
polyomaviruses, including Merkel cell polyomavirus, which causes an aggressive skin cancer [37,38].
These discoveries have led to resurgence in interest in polyomavirus biology and to the roles of virus
encoded proteins in pathogenesis. In this regard, two members of the family have recently been
shown to encode proteins with viroporin characteristics.
2.1. JC Virus Agnoprotein
In 1958, progressive multifocal leukoencephalopathy (PML), a potentially fatal demyelinating
disease of the brain, was discovered and later attributed to a novel polyomavirus termed JC [39].
JC is widespread amongst the adult population, with studies suggesting infection rates are upwards
of 35%, and possibly as high as 90% [40]. Despite the high prevalence, PML incidence is extremely
low due to the tendency of JC to result in an asymptomatic latent infection of the kidneys, lymphatic
system and bone marrow in immunocompetent individuals [41]. Activation of the virus occurs
almost exclusively in immunocompromised patients and is characterised by a lytic infection of
oligodendrocytes resulting in demyelination and development of PML, although it is not clear when
the virus infects the central nervous system. Before the introduction of antiviral therapies to combat
the progression to AIDS, PML was a prominent feature of the HIV phenotype. Since then, there
has been a resurgence in PML cases as a wide range of immunosuppressant therapies are being
applied to combat autoimmune diseases such as multiple sclerosis (MS) and aid in the acceptance
of transplanted tissues [42]. Links between JC and a range of human cancers have also been reported,
although these are disputed [43].
Similar to most polyomaviruses, JC encodes for early proteins, which constitute the small and
large T antigens and their many splice variants, which engage with many host processes to ensure
a cellular milieu is available that is conducive to virus replication. In addition to this, three late
structural proteins are expressed. These include the major capsid protein, VP1, and the VP2/VP3
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minor capsid proteins [33]. JC encodes for an additional late protein termed agnoprotein [44].
Agnoprotein is only expressed by a limited number of polyomaviruses including the related BK
and SV40.
The 71 amino acid agnoprotein is highly basic and contains a central hydrophobic region capable
of forming an amphipathic helix [45,46]. In concert with residues in the amino terminal region, this
amphipathic helix is required for localization to the ER and membrane insertion [11]. Biochemical
analysis shows that residues 30-37 within the amphipathic helix are necessary and sufficient for
dimer and oligomer formation [45]. Agnoprotein oligomers are stable in SDS and do not depend
on disulphide bridge formation [45]. Recent nuclear magnetic resonance (NMR) data confirmed the
formation of an amphipathic helix between Leu23 and Phe39 [46]. The basic nature of the protein
may provide flexibility within the amino and carboxyl termini increasing the range of interactions
with host partners. For a list of known JC agnoprotein binding partners see Table 1.
Table 1. Known JC agnoprotein binding partners [44]. Function and region of interaction are stated
if known.
Host Encoded Interacting
Partner
Function Region of Agnoprotein
Required for The
Interaction
AP-3 (δ subunit) Modulates vesicle trafficking, prevents
agnoprotein degradation
Residues 1–12
PP2A Dephosphorylation of JC agnoprotein Residues 18–36
FEZ1 Facilitates virus release Unknown
Tubulin Unknown Unknown
HP-1α Nuclear egress of JC virions N-terminus
p52 Unknown Unknown
p53 Modulation of the cell cycle N-terminus
p103 Unknown Unknown
p112 Unknown Unknown
p158 Unknown Unknown
Ku70 Host cell DNA repair N-terminus
YB-1 Altered host gene expression Residues 18–36
Virus encoded interacting
partner
Function Region of agnoprotein
required for the
interaction
JC T-antigen Repression of JC transcription and DNA
replication
N-terminus
JC t-antigen Disruption of the PP2A – t-antigen interaction N-terminus
HIV-1 Tat Inhibition of HIV1 gene expression Residues 18–54
Viroporin activity is associated with increased plasma membrane permeability, resulting in
elevated cytosolic calcium levels [11]. Similar to several known viroporins, agnoprotein expression
manipulates host trafficking pathways to allow transport of agnoprotein to the cell surface to mediate
plasma membrane permeabilization [47]. To achieve this, agnoprotein interacts with the δ sub-unit of
adaptor protein complex 3 (AP-3), inhibiting its function and as a consequence preventing trafficking
of agnoprotein to the lysosome for destruction. Substitution of two basic amino acids in the
amino terminal region of agnoprotein (Arg8/Lys9) prevented the interaction with AP-3, perturbed
sub-cellular localization and abrogated the plasma membrane permeabilization seen with the wild
type protein. Moreover, JC viruses containing either an agnoprotein deletion or alanine substitution
of the basic residues resulted in a comparable defect in virion release from infected cells [11,47].
The conclusion of these studies is that the basic residues are a critical requirement for agnoprotein
function, potentially by contributing towards viroporin activity. Mutations of a similar basic motif
in the HCV p7 protein also impaired viroporin activity, as assessed using a carboxylfluorescein dye
release assay, however, further investigation in fact revealed that the mutant protein was no longer
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able to integrate correctly into membranes [10]. It is plausible that by mutating the basic loop in
agnoprotein, membrane integration has been perturbed which would be expected to have broader
impacts on agnoprotein function beyond inhibiting viroporin function.
Agnoprotein has multiple roles within the JC life cycle, and some of these are known to require
residues within the amphipathic helix, and as such may depend upon viroporin function. Binding of
the Large T antigen to the viral origin of replication is enhanced in the presence of agnoprotein [45].
Agnoproteins containing mutations that would be expected to impair amphipathic helix formation
display decreased Large T binding and significantly reduced virus genome replication [45]. Some
mutations within the amphipathic helix impact protein stability, resulting in reduced agnoprotein
expression [46]. As such the impact on virus replication might arise as a result of less agnoprotein
rather than loss of putative viroporin activity. Nevertheless, reduced JC replication is a feature
observed in some agnoprotein deletion viruses, indicating that modulation of replication is a bona
fide function of agnoprotein [48].
As polyomavirus virions assemble in the nucleus, they are first required to exit this organelle
into the cytoplasm prior to the egress from the infected cell [49]. Since complete lysis of the nuclear
membrane would abolish the integrity of the infected cell and impair virus replication, JC has evolved
to instead alter the nuclear envelope (NE) to mediate virus egress. JC infected cells show protrusions
and invaginations in the NE, mediated through binding of agnoprotein to heterochromatin protein-1
(HP-1) [50]. HP-1 normally interacts with the Lamin-B receptor (LBR) to assist with the reassembly
of the NE after cell division [51]. However, the amino terminal domain of agnoprotein is capable of
binding to HP-1 inducing disassociation from LBR and resulting in morphological changes to the NE,
allowing escape of progeny virions [50]. Whether viroporin activity is required for this function is
not clear, although binding to HP-1 requires the amino terminal 24 residues, which are outside the
putative TMD.
Agnoprotein has been shown to be subject to extensive post-translation modification and this
is likely a key regulator of function. Protein kinase C (PKC) can phosphorylate JC agnoprotein on
three identified residues; Ser7, Ser11 and Thr21 [52]. JC viruses containing alanine substitutions
at these sites were less able to maintain an active infection, although they displayed enhanced
agnoprotein expression levels at early time points during infection. Subsequent studies identified
an antagonistic role for protein phosphatase 2A (PP2A) in agnoprotein phosphorylation [53].
Agnoprotein dephosphorylated by PP2A was shown to inhibit JC replication to levels comparable
with the alanine substitution mutants. Mechanistically, JC small T antigen has been shown to bind
to both PP2A and agnoprotein, and is thought to reduce the ability of PP2A to dephosphorylate
agnoprotein [53]. Interestingly, depletion of PP2A from JC infected cells using siRNA also resulted in
reduced virus replication [53]. This raises the intriguing possibility that both phosphorylated and
de-phosphorylated forms of agnoprotein have defined functions, and interplay between the two
contributes to the successful replication and propagation of JC. These functions, however, have yet
to be delineated. Phosphorylation has been shown to be important in regulating the sub-cellular
localization of proteins, as such it is plausible that the phosphorylation state of agnoprotein
may determine its sub-cellular location and hence the role it plays in replication. Whether it is
also required to regulate viroporin function has not been shown. However, given the findings
of Sawa and colleagues that viroporin function is needed at the cell surface, it is a possibility
that phosphorylation of agnoprotein may also contribute to localizing the channel to where it is
required [47]. Regulation of viroporins by post-translational modifications would add another tier
of control to these important proteins.
JC agnoprotein shares significant identity with the agnoproteins encoded by the related viruses
BK and SV40 (60% across the whole protein, rising to 90% in the amino terminal region) [44] (Figure 1).
As expected from such a high homology, agnoproteins of BK and SV40 appear to perform similar
functions during the virus life cycle, although with some subtle differences. Though less well studied,
loss of agnoprotein appears to correlate with defects in the late stages of the virus life cycle and to
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perturb egress. In addition, agnoprotein may also play a role in packaging the SV40 genome [48].
BK egress has recently been shown to be sensitive to the DIDS compound [54]. Given that DIDS is a
broad-spectrum inhibitor of ion channels, it is possible that the target of its actions is an agnoprotein
viroporin. It would be interesting to assess the impact of DIDS on virus egress from an agnoprotein
knockout virus.
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Figure 1. Sequence conservation of BK, JC and SV40 agnoproteins. Residues are displayed using 
amino acid single letter codes. Conserved residues are shown in red through to unconserved 
residues in blue. * represents a residue conserved across all three sequences. Uniprot sequences 
P03085 (BK), P03086 (JC) and P03084 (SV40) were used. The sequence alignment was generated using 
the online PRALINE multiple sequence alignment tool 
(http://www.ibi.vu.nl/programs/pralinewww/). 
The wide-ranging roles of agnoproteins identified from both JC and BK coupled with the 
deleterious effects seen in the agnoprotein deficient viruses warrants a serious analysis of the 
potential for agnoprotein as a target of direct acting antiviral therapeutics. Groups have previously 
generated siRNA to target JC agnoprotein and have had success of inhibiting viral replication in 
mice infected brains, justifying the premise of targeting this protein for inhibition [55]. Such studies 
would be expedited by a direct analysis of channel activity using recombinant agnoprotein, similar 
to the pioneering work on the HCV p7 protein [56]. Not only would this affirm channel function but 
would also provide a platform from which to screen the large libraries of compounds displaying 
viroporin inhibitory properties available. 
2.2. SV40 Late Proteins 
Three late proteins have been shown to aid in SV40 entry and release by virtue of their  
viroporin-like properties. VP2 and VP3 are generated from successive Met residues within the VP2 
messenger RNA so they share a common carboxyl-terminus. They are classed as minor constituents 
of the virus particle, being present at a stoichiometry of one copy of a VP2 or VP3 protein per VP1 
pentamer [57]. Given that SV40 is a non-enveloped virus, it has evolved strategies to allow transport 
of the incoming virion through the membranous environment of the cytoplasm to the nucleus to 
initiate genome replication. A number of studies have shown that both VP2 and VP3 form pores in 
cellular membranes and may aid in delivery of the SV40 virion into the nucleus [58,59]. Mutation of 
residues within putative TMD prevented membrane targeting and when engineered into SV40 
genomes resulted in reduced infectivity [60]. 
SV40 also encodes a unique very late protein termed VP4, encoded by the same transcript as 
VP2/VP3. Unlike other late proteins, VP4 is thought not to be incorporated into SV40 capsids. VP4 
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of residues within putative TMD prevented membrane targeting and when engineered into SV40
genomes resulted in reduced infectivity [60].
SV40 also encodes a unique very late protein termed VP4, encoded by the same transcript as
VP2/VP3. Unlike other late proteins, VP4 is thought not to be incorporated into SV40 capsids.
VP4 encodes a single TMD and associates with membranes, where it generates a channel of defined
pore size and increases membrane permeability. VP4 is expressed at least 24 h later than other late
proteins, indicating a potential role in virus release [61]. VP4 channel activity is regulated by the lipid
environment and shows a greater activity in liposomes mimicking the composition of the plasma
membrane, and SV40 viruses lacking VP4 exhibit a significant defect in virus spread. Together,
these data indicate that VP4 is a viroporin that functions specifically during the latter stages of the
SV40 life cycle [61–64]. Whether other mammalian polyomaviruses encode a VP4 protein is not
clear. It is currently uncertain why SV40 might require VP4 when other polyomaviruses do not.
JC agnoprotein has been shown to permeabilize the plasma membrane [11], and may therefore fulfil
this role. However, given the sequence similarity it is likely that SV40 agnoprotein may also serve as a
viroporin. It is possible that there is either redundancy or co-operation between agnoprotein and VP4.
These questions will remain unanswered until viroporin function is confirmed in SV40 agnoprotein.
3. Papillomaviruses
The Papillomaviridae contains an extensive array of different papillomavirus (PV) types capable
of infecting a variety of animal species, of which at least 170 have currently been isolated from
humans [65]. Like Polyomavirus, they are small, non-enveloped double stranded DNA viruses
around 55 nm in diameter [66]. Most PV encode six early (E1, E2, E4, E5, E6 and E7) and two
late structural genes (L1 and L2). Approximately 12 HPV types, termed high-risk, are the causative
agents of several ano-genital and oral malignancies [67]. Of these, HPV16 and HPV18 are the most
important and are responsible for approximately 70% of the cervical cancer cases, and for the deaths
of approximately 270,000 women in 2012 alone [66]. Low risk HPV are usually cleared by the body
and vaccines are available for prophylactic treatment of high risk HPV, but there is as of yet no
therapeutics for existing cases of HPV infection.
3.1. HPV16 E5
Three gene products E5, E6 and E7 mediate the transforming potential of high-risk HPV. E6
and E7 are the major drivers of keratinocyte proliferation [68]. They are necessary to maintain
the cell cycle of differentiating keratinocytes and they achieve this by binding to and inactivating
the Retinoblastoma (pRb) and p53 tumor suppressor proteins [68]. Repression of E6 and E7 in
various cell lines has been shown to induce cellular senescence and halt differentiation. The E5
protein is the least understood of the three oncoproteins [69]. HPV16 E5 is a highly hydrophobic,
83 amino acid membrane protein that resides in the lumen of cytoplasmic membranes and interacts
with a growing number of cellular partners [3,69–73] (Figure 2A). The triple membrane spanning
topology of HPV16 E5 was determined by partial membrane permeabilization fluorescence studies
in cells and these support the idea that the E5 amino terminus resides in the lumen of the ER with
a carboxyl terminus exposed to the cytosol [74]. Lack of specific antibodies preclude localization
studies from virus infected cells, however, epitope tagged E5 has been shown by over-expression
studies to predominantly localize to ER and Golgi membranes [73]. Cell surface localization has also
been noted [75], although this has been disputed by others [74]. Sequence analysis demonstrates
that a recognizable E5 gene is missing from several HPV types (beta, gamma and mu). Further,
viruses that do encode an E5 open reading frame show significant sequence divergence, with the
resulting protein product ranging in size from approximately 40–90 amino acids. Such significant
divergence might indicate distinctive roles for E5 within the HPV life cycle, dependent on the specific
virus type. Importantly, all high-risk cancer causing HPV types encode an E5 protein similar to
HPV16, of approximately 80 acids termed E5 alpha [76]. HPV16 E5 oligomerizes in vitro and in
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cells, with oligomer formation driven not by the presence of disulphide linkages between cysteine
residues, rather by hydrophobic interactions between individual monomers [3,77]. In 2012 our
laboratory demonstrated that the E5 oligomer could mediate the controlled release of the small
molecule carboxyflourescein using a liposome dye release assay [3]. Whilst some questions have
been raised as to the validity of this indirect measure of channel activity [78], it has been widely used
with multiple channels (e.g., HCV p7, classical swine fever virus (CSFV) p7, respiratory syncytial
virus (RSV) SH), and has provided important insights into their activity [31,79,80]. The stoichiometry
of HPV16 E5 was predicted to be hexameric using in silico modelling and subsequently confirmed by
native PAGE electrophoresis and transmission electron microscopy [3] (Figure 2B). These complexes
displayed channel-forming activity with a defined pore size, and activity was increased in acidic pH.
Sensitivity of E5 to the adamantane derivative Rimantadine [3] and the alkyl imino-sugar NN-DNJ
(our unpublished data) was demonstrated in vitro, as well as to a novel small molecule inhibitor
generated using in silico modelling of the E5 channel and subsequent docking analysis [3].
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permeabilization assays demonstrate that the carboxyl-terminus extends into the cytosol while the 
amino-terminus is directed towards the endoplasmic reticulum (ER) lumen. The first TMD gives rise 
to the subcellular localization of E5 and mediates binding to MHC class I molecules and Calnexin. 
The second TMD facilitates the recently identified interaction with the transmembrane protein YIPF4 
as well as the 16K subunit of the H+-ATPase. Further functions of E5 such as the increase of 
koilocytosis, activation of EGFR signaling and induction of endosome alkalinization are exerted via 
the third TMD; (B) The sequence of HPV16 E5 was obtained from Uniprot and the secondary 
structure predicted using PSIPRED and MEMSAT-3 and energy minimized. The model for an E5 
monomer contained three TMD and had the lowest energy and was used to build a hexameric model 
using the protocol described previously [81]. Each monomer in the model was minimized 
individually to restore the symmetry and was refined using prime2 (Schrodinger Inc). The oligomeric 
state of HPV16 E5 was confirmed by native PAGE and transmission electron microscopy [3]. 
E5 expression induces anchorage-independent growth in murine NIH3T3 cells and mitogenic 
effects in primary human foreskin epithelial cells [82,83]. Transformation has been recapitulated  
in vivo using transgenic mouse models where E5 is expressed in epithelial cells under the control of 
the Keratin-14 promoter. In these mice, E5 expression was associated with hyperplasia and tumor 
formation [84,85]. A number of studies have demonstrated the importance of the epidermal growth 
factor (EGF) receptor (EGFR) for E5-induced transformation [86,87], and these have since been 
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E5 expression induces anchorage-independent growth in murine NIH3T3 cells and mitogenic
effects in primary human foreskin epithelial cells [82,83]. Transformation has been recapitulated
in vivo using transgenic mouse models where E5 is expressed in epithelial cells under the control
of the Keratin-14 promoter. In these mice, E5 expression was associated with hyperplasia and
tumor formation [84,85]. A number of studies have demonstrated the importance of the epidermal
growth factor (EGF) receptor (EGFR) for E5-induced transformation [86,87], and these have since been
reinforced by genetic studies which showed that transgenic mice expressing E5 failed to produce
tumors when crossed with mice encoding for an inactive EGFR [85]. Thus the contribution of
E5 to host cell transformation appears dependent on manipulation of the EGFR. Studies aimed
at understanding the role of E5 in the productive HPV life cycle show that E5 is required to
maintain the proliferative status of infected cells as they undergo terminal differentiation, in order
to allow virus genome replication. Moreover, E5 causes a delay to the early stages of keratinocyte
differentiation to achieve this. Using small molecule inhibitors targeting EGFR we have been able to
show that these processes are also dependent on active EGFR signalling (our unpublished data). The
precise mechanism by which E5 manipulates the EGFR is unclear. The current consensus model
is that E5 expression is associated with a deacidification of endosomes [88]. This prevents the
normal degradative trafficking pathways, which would culminate in deposition of active EGFR in
the lysosome and termination of EGFR signalling. In E5 expressing cells active EGFR appears to
be re-routed into recycling endosomes and returned to the plasma membrane, where it maintains
mitogenic signalling [87]. Deacidification of endosomes might result from specific interactions
with host binding partners [89], or, similar to IAV M2 and hepatitis C virus p7, might indicate
a requirement for direct proton channel activity [10,17]. In support of this idea, enhanced EGFR
signalling observed in E5 expressing cells was reduced by the small molecule inhibitors that
prevented carboxyfluorescein release in the in vitro dye release assays [3]. These data suggest that the
oncogenic activity of E5 may be directly linked to viroporin function. If this proves to be the case then
E5 would represent the first example of an oncogenic viroporin. The development of specific mutant
E5 proteins that lack channel activity will need to be tested in these assays in order to validate the
small molecule inhibitor studies, which can be fraught with off-target effects. Moreover, it will be of
great interest to generate viruses containing these mutants in order to study at what stage of the HPV
life cycle any putative viroporin function is necessary. The viroporin function was described for E5
from HPV16 [5]. Given that E5 proteins from the other high-risk HPV types are predicted to adopt a
similar three TMD topology, it will be of interest to determine whether viroporin function is conserved
amongst this group of viruses. Whilst the presence of a defined pore size of <2 nm was confirmed
in these studies [5], future work should focus on determining the ion selectivity of the E5 channel to
conclusively determine whether there is a preference for protons or whether ion selectivity fluctuates
dependent on the particular membrane environment, as has been shown for other viroporins [90].
Finally, although E5 is not thought to be expressed in cervical cancer cells due to the integrated nature
of the genome [69], it is postulated to play a role in the early stages of cancer development. Given the
limited treatment options for those already infected with HPV, ongoing research into the development
of E5 inhibitors with greater potency suited to drug development programs appears feasible given
our findings [3]. Thus, there is potential for drug development targeting E5, yet whether this will
ultimately prove relevant in the post-vaccination era remains to be seen.
4. Concluding Remarks
Viroporins are multi-faceted viral proteins shown to play key roles in the life cycles of a number
of important human pathogens. The relatively recent identification of such proteins encoded by small
DNA tumor viruses offers the opportunity to understand their contribution towards the productive
life cycle of these viruses and ultimately their pathogenesis. Analysis of viroporin deletion mutants in
these viruses will undoubtedly help to delineate their functions and may provide an important insight
into how they manipulate critical host functions. The large economic and health burden associated
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with virus infection, alongside the rapid increase in resistance to existing therapeutic regimes, if
available, demonstrates the need for new anti-viral drugs. Given the low mutation rate of DNA virus
genomes, identifying virus encoded targets as exemplified by the viroporins presents an attractive
target for future therapeutics. Increasing understanding of viroporin structure and function, along
with the advent of high throughput technologies will hopefully lead to the development of these
much needed treatments.
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